Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Rifabutin dose must be increased in patients taking efavirenz

A study of patients with HIV and tuberculosis has confirmed that the recommended dose adjustment of rifabutin (Mycobutin) in patients also taking efavirenz (Sustiva) produces

Published
07 October 2005
By
Christopher Gadd
Efavirenz may linger for up to eight weeks after treatment stops

Levels of efavirenz (Sustiva) sufficient to cause drug resistance may linger for at least eight weeks after it is stopped in some people who have

Published
28 September 2005
By
Keith Alcorn
Nevirapine paediatric dosing: adult tablets can be split, Thai study reports

Dosing of children with fractions of adult fixed dose combination tablets that contain nevirapine (Viramune) can provide the appropriate nevirapine exposure for children of varying

Published
13 September 2005
By
Keith Alcorn
Efavirenz and rifampicin: UK doctors caution on higher EFV doses in Africans (corrected)

Clinicians at St George's Hospital in London report that patients are much more likely to experience efavirenz-related side-effects when 800mg efavirenz (Sustiva) is co-administered with

Published
08 September 2005
By
Edwin J. Bernard
Aging HIV population cause for concern

A hidden epidemic of HIV infection may be occurring amongst older individuals, suggests Dr Nathalie Casau of the Albert Einstein College of Medicine, New York,

Published
05 September 2005
By
Edwin J. Bernard
IAS: Rifampin TB treatment does not reduce response to NNRTIs, South Africans report

Using rifampin-based therapy alongside a triple antiretroviral regimen that contains drugs from the NNRTI class (either nevirapine or efavirenz) does not result in a poorer

Published
08 August 2005
By
Keith Alcorn
IAS: New tablet formulation of Kaletra is on its way, manufacturer says

Abbott Laboratories, the manufacturers of ritonavir-boosted lopinavir (Kaletra) announced the development of a new tablet formulation of the protease inhibitor on July 27th at the

Published
29 July 2005
By
Christopher Gadd
Nevirapine lingers for two weeks after mums give birth

Dutch researchers this week confirmed the Thai findings reported last year, showing that women exposed to a single dose of nevirapine (Viramune)may still have detectable

Published
14 July 2005
By
Keith Alcorn
Efavirenz reduces blood statin concentrations

Taking efavirenz (Sustiva) at the same time as the lipid-lowering statin drugs simvastatin (Zocor), atorvastatin (Lipitor) or pravastatin (Lipostat) results in reduced concentrations of the

Published
29 June 2005
By
Christopher Gadd
XIV International HIV Drug Resistance Workshop: Clinical response

Two studies of atazanavir (ATV, Reyataz) and ritonavir (RTV, Norvir) focused on cut-off values that would help determine response to treatment. Eoin Coakley from Virologic

Published
22 June 2005
By
Yasmin Halima

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.